Ftse Mib
35.959,89
-0,51%
DAX
20.974,60
-0,14%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
104.557,82
2,48%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Tango Therapeutics Inc (TNGX) Tango Therapeutics Inc (TNGX) Notizie

TNGX

Tango Therapeutics (TNGX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TNGX
DataOraFonteTitoloSimboloCompagnia
13/01/202513:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
02/01/202513:07Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
03/12/202413:00Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
27/11/202413:00Business WireTango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
20/11/202422:24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TNGXTango Therapeutics Inc
19/11/202401:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
08/11/202403:35Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
07/11/202403:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
06/11/202413:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
06/11/202413:05Business WireTango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
06/11/202413:00Business WireTango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development ProgramNASDAQ:TNGXTango Therapeutics Inc
23/10/202402:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
28/08/202413:00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
07/08/202413:00Business WireTango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
05/06/202413:00Business WireTango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
23/05/202415:18PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
23/05/202413:00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
08/05/202413:00Business WireTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
18/03/202412:00Business WireTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
05/03/202422:47GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:TNGXTango Therapeutics Inc
31/01/202413:00GlobeNewswire Inc.Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TNGXTango Therapeutics Inc
04/01/202408:47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyNASDAQ:TNGXTango Therapeutics Inc
03/01/202413:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
08/11/202313:00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
07/11/202313:00GlobeNewswire Inc.Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
18/10/202323:23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
18/09/202313:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
12/09/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TNGXTango Therapeutics Inc
06/09/202313:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TNGX

La tua Cronologia

BIT
Q00576
Leonteq Securities
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network